Search Results

You are looking at 1 - 10 of 69 items for :

  • "bisphosphonates" x
  • User-accessible content x
Clear All
Full access

Richard L. Theriault

1997 ; 89 : 309 – 319 . 31 Roodman GD . Biology of osteoclast activation in cancer . J Clin Oncol 2001 ; 19 : 3562 – 3571 . 32 Mundy GR Yoneda T Hiraga T . Zoledronic acid and other bisphosphonates: Impact on the bone

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias and Giovanni Casazza

P reclinical studies show that bisphosphonates may have antitumor activity in addition to their ability to reduce osteoclast-mediated bone resorption. 1 These effects include prevention of tumor cell adhesion to bone and consequently prevention

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch and Alfred I. Neugut

morbidity of bone disease in these patients, guidelines from NCCN, ASCO, International Myeloma Working Group, and European Myeloma Network all recommend use of the bisphosphonates zoledronic acid and pamidronate in patients receiving primary MM therapy. 2

Full access

Joanne Mortimer and Mary Mendelsohn

with the guideline recommendations regarding the use of intravenous bisphosphonates in women with metastatic bone disease. Given the importance of bone-directed therapies in decreasing the incidence of skeletal-related complications in breast cancer

Full access

Mohamad A. Hussein

lesions of multiple myeloma: a phase III, double-blind, comparative trial . Cancer J 2001 ; 7 : 377 – 387 . 31. Djulbegovic B Wheatley K Ross J . Bisphosphonates in multiple myeloma . Cochrane Database Syst Rev 2001 ; 4 : CD003188

Full access

Charise Gleason, Ajay Nooka and Sagar Lonial

reduces skeletal-related events in patients with osteolytic metastases . Cancer 2001 ; 91 : 1191 – 1200 . 48 Mehrotra B Ruggiero S . Bisphosphonate complications including osteonecrosis of the jaw . Hematology Am Soc Hematol Educ Program

Full access

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud and Joan M. Neuner

receiving intravenous bisphosphonates at intervals less than 90 days were excluded. Medicare files from 2 years before until 6 months after AI initiation were the source of cohort members' demographic data, outpatient and inpatient diagnoses, and

Full access

Kathleen Harnden and Kimberly Blackwell

Bisphosphonates are an integral part of treatment for bone metastases in many malignancies, including breast cancer. Bone metastases can have devastating consequences, including severe pain, fractures, hypercalcemia, and spinal cord compression

Full access

Ruben Niesvizky and Ashraf Z. Badros

effect recently documented in MM and other cancers, ONJ is linked to long-term use of bisphosphonates. The incidence of ONJ in bisphosphonate-treated MM patients is unknown. Manufacturer-sponsored epidemiologic studies report an incidence ranging from 0

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas and Catherine H. Van Poznak

postmenopausal women: recommendations and rationale . Ann Intern Med 2002 ; 137 : 526 – 528 . 8 Hillner BE Ingle JN Chlebowski RT . American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women